Tella Incorporation operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Tella Incorporation with three other
companies in this sector in Japan:
Trans Genic Inc
sales of 2.29 billion Japanese Yen [US$20.89 million]
of which 48%
was CRO Business),
Japan Tissue Engineering Company Limited
(1.43 billion Japanese Yen [US$13.05 million]
of which 93%
was Regenerative Medicine Products Business), and
Medinet Co., Ltd.
(1.91 billion Japanese Yen [US$17.41 million]
of which 98%
was cell processing).
Tella Incorporation reported sales of ¥1.80 billion (US$16.43 million)
December of 2016.
decrease of 5.6%
versus 2015, when the company's sales were ¥1.91 billion.
Contributing to the drop in overall sales was the 21.9% decline
in Cell Therapy Technology Development Busi, from ¥1.03 billion to ¥807.08 million.
However, these declines were partially offset by the increase in sales of
Cell Therapy Support Business (up 19.2% to ¥994.76 million)